Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560509 | 0.91 | TYK2 (0.36) | TYK2HTR1ASYKBRD4NPC1 | |
| SCHEMBL15091214 | 0.90 | SYK (0.45) | SYK | |
| SCHEMBL15091265 | 0.86 | PDE4A (0.40) | TYK2SYKNPC1ALDH1A1RAB9A | |
| SCHEMBL15120647 | 0.84 | TYK2 (0.34) | TYK2HTR1A | |
| SCHEMBL18561147 | 0.78 | SYK (0.42) | SYK | |
| SCHEMBL18560616 | 0.77 | SYK (0.45) | SYK | |
| SCHEMBL15091249 | 0.77 | SYK (0.44) | SYK | |
| SCHEMBL15091254 | 0.76 | SYK (0.53) | SYK | |
| SCHEMBL3575849 | 0.74 | ALDH1A1 (0.46) | HTR1ASYKNPC1ALDH1A1RAB9A | |
| SCHEMBL3582329 | 0.73 | TNIK (0.43) | LMNAHTR1ANPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802567-B1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | SYK, BTK, IRAK2 | LMNA 4808/4885TYK2 6/4885HTR1A 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.